Changes to Speech Production after SpeechVive Treatment in Individuals with Parkinson’s Disease
Objective: The purpose of the present study was to assess the effects of a device-driven treatment (SpeechVive) on respiratory and laryngeal function after 8 weeks…Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease (PD) patients with persistent motor fluctuations: results of the 1-year open-label phase of the TOLEDO study
Objective: To evaluate the long-term safety and efficacy of apomorphine infusion (APO) in PD patients with motor fluctuations despite optimised oral therapy. Background: The randomised,…Risk Thresholds of Levodopa Dose for Dyskinesia in Chinese Patients with Parkinson’s Disease: A Pilot Study
Objective: The objective of this study was to investigate the thresholds of levodopa dose to reduce the risk for dyskinesia in a Chinese PD population.…Smartphone software for home monitoring of motor symptoms in Parkinson’s disease – The CloudUPDRS Smartphone Software in Parkinson’s (CUSSP) study
Objective: To determine the validity of smartphone software for objective monitoring of motor symptoms in patients with Parkinson’s disease (PD). Background: Although the MDS-Unified Parkinson’s…Parotitis as Adverse Event Following BoNT Injections for Sialorrhea
Objective: Review potential adverse events of parotitis with botulinum toxin injections for sialorrhea. Background: Sialorrhea is a common non-motor symptom of Parkinson’s disease. Botulinum toxin…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and Clinical Global Impression of Change from the BIPARK-I double-blind experience
Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations, the patients’ and clinicians’ perception of PD symptoms improvement [as assessed by…NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson’s Disease: Study Design and Status Update
Objective: To assess the safety and tolerability of nilotinib (150-300 mg once daily) in moderate/advanced Parkinson’s disease (PD). Background: Nilotinib is approved by the FDA…Identification of candidates for device-assisted therapy in Parkinson’s disease using Artificial Neural Networks
Objective: To use Multilayer Perceptron (MLP), an artificial neural network, to identify candidates for device-assisted therapy (DAT) among patients with Parkinson's disease (PD) Background: DAT…Supportive treatments for Ataxia, a Randomized Control Trial
Objective: The objective of this study is to evaluate the effectiveness of supporting treatments that improve awareness and the quality of patient life and counsel…A homozygous pentanucleotide repeat expansion in cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS)
Objective: To identify the genetic cause in patients with CANVAS recruited at the University Hospital of Schleswig-Holstein, Campus Lübeck. Background: CANVAS is a late-onset neurological…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 217
- Next Page »